In both NSCLC and HCC, we showed that pre-treatment with HK2 inhibitor enhanced the total tube length, branch points, and number in HUVEC co-cultured with TPC, when compared with HUVEC co-cultured with placebo pre-treated TPC (Fig. 5a–d). This evidence concerns the gene HK2 and hepatocellular carcinoma.